Early research shows that overall survival is longer with ramucirumab and pembrolizumab (RP) compared with an investigator’s choice standard-of-care (SOC) in advanced non-small cell lung cancer (NSCLC).
For patients with non-small cell lung cancer (NSCLC), delaying surgical procedures for more than 12 weeks is associated with an increased risk for recurrence and worse survival.
Researchers evaluated data on clinical outcomes among 107,000 patients from the National Inpatient Sample who had both cancer and atrial fibrillation.
A considerable proportion of patients with lung cancer are prescribed medications that prolong the corrected QT interval, limiting their eligibility for clinical trials.
Among former male smokers, higher cardiorespiratory fitness is independently linked to a lower risk for lung cancer incidence.
To investigate the association between this commonly used antihypertensive class and lung cancer, researchers conducted a population based cohort study involving 992,061 patients from the United Kingdom Clinical Practice Research Datalink.
Researchers found a significant correlation between glycemic index and lung cancer risk, more pronounced among “never smokers,” for squamous cell carcinoma, and for those with less than 12 years of education.
